AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23039319 — intervention group
Group type: COMPARATOR
Intervention: Cefdinir (14 mg/kg/day for 5 days)
Number of subjects: 330
Study 20657877 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable collagen barriers supported by osteosynthesis plates
Number of subjects: 22
Study 20657877 — intervention group
Group type: COMPARATOR
Intervention: Nonresorbable titanium‐reinforced expanded polytetrafluoroethylene barriers
Number of subjects: 22
Study 18320518 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral retinal scatter photocoagulation
Number of subjects: 101
Study 18320518 — intervention group
Group type: COMPARATOR
Intervention: Untreated (natural course disease)
Number of subjects: 101
Study 15994038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribulus terrestris extract (20 mg/kg body weight per day)
Number of subjects: 21
Study 15994038 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribulus terrestris extract (10 mg/kg body weight per day)
Number of subjects: 21
Study 15994038 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 21
Study 12538203 — intervention group
Group type: COMPARATOR
Intervention: Control (no risk or pain)
Number of subjects: 150
Study 12538203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain (pain but no risk)
Number of subjects: 150
Study 12538203 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk (risk but no pain)
Number of subjects: 150
Study 12538203 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding risk or pain (all groups)
Number of subjects: 150
Study 12538203 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding risk or pain (participants who understood)
Number of subjects: 150
Study 12538203 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants agreeing to participate without understanding risks
Number of subjects: 150
Study 12538203 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling pressured to participate
Number of subjects: 150
Study 10434219 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-N2O group
Number of subjects: 69
Study 10434219 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone group
Number of subjects: 69
Study 10434219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study 7876773 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention shifts to one's name
Number of subjects: 34
Study 2131860 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Lungs collapsed (0/0)
Number of subjects: 90
Study 2131860 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Static inflation with +5 cm H2O and F1O2 1.0 (+5/1.0)
Number of subjects: 90
Study 2131860 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Static inflation with +5 cm H2O and F1O2 0.21 (+5/0.21)
Number of subjects: 90
Study 2131860 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: Static inflation with +15 cm H2O and F1O2 1.0 (+15/1.0)
Number of subjects: 90
Study 2131860 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 5: Static inflation with +15 cm H2O and F1O2 0.21 (+15/0.21)
Number of subjects: 90
Study 2131860 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 6: Controlled mechanical ventilation (PEEP +5 cm H2O; F1O2 1.0)
Number of subjects: 90
Study 142579 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozotocin plus 5-fluorouracil
Number of subjects: 116
Study 142579 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozotocin plus cyclophosphamide
Number of subjects: 116
Study 31146548 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV self-testing (HST)
Number of subjects: 0
Study 31146548 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based testing
Number of subjects: 0
Study 31463821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual SAM 10 mg
Number of subjects: 55
Study 31463821 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral SAM 10 mg
Number of subjects: 55
Study 31463821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous SAM
Number of subjects: 55
Study 31463821 — intervention group
Group type: COMPARATOR
Intervention: Oral SAM 10 mg under fed conditions (cohort 1)
Number of subjects: 55
Study 31463821 — intervention group
Group type: COMPARATOR
Intervention: Oral SAM 10 mg for young and elderly participants
Number of subjects: 55
Study 28113118 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use partnerships (sexual/romantic partnerships)
Number of subjects: 134
Study 28113118 — intervention group
Group type: EXPERIMENTAL
Intervention: Racially concordant partnerships reported by white study participants
Number of subjects: 134
Study 28113118 — intervention group
Group type: EXPERIMENTAL
Intervention: Racially discordant partnerships reported by African American study participants
Number of subjects: 134
Study 28113118 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnerships where either member witnessed the other experience an overdose
Number of subjects: 134
Study 25195970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 1499
Study 25195970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1499
Study 23741995 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting + Er:YAG laser irradiated
Number of subjects: 200
Study 23741995 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting
Number of subjects: 200
Study 23741995 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiated + liner applied
Number of subjects: 200
Study 23741995 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting + Nd:YAG laser irradiated
Number of subjects: 200
Study 23741995 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser irradiated + liner applied
Number of subjects: 200
Study 23741995 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 200
Study 23741995 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasted + liner applied
Number of subjects: 200
Study 23741995 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasted + Nd:YAG laser irradiated
Number of subjects: 200
Study 23741995 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiated
Number of subjects: 200
Study 23741995 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasted + Er:YAG laser irradiated
Number of subjects: 200
Study 21536404 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE/Gore grafts
Number of subjects: 99
Study 21536404 — intervention group
Group type: COMPARATOR
Intervention: polyester/Braun grafts
Number of subjects: 99
Study 21536404 — intervention group
Group type: COMPARATOR
Intervention: polyester/Vascutek grafts
Number of subjects: 99
Study 18562974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive interventions targeting walking behavior
Number of subjects: 14
Study 18562974 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief telephone prompts
Number of subjects: 14
Study 18562974 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions to walk 5-7 days/week
Number of subjects: 14
Study 18562974 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions to walk at moderate intensity
Number of subjects: 14
Study 18562974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediated interventions delivering physical activity promotion materials through non-face-to-face channels
Number of subjects: 14
Study 18562974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass media campaigns targeting broader audiences
Number of subjects: 14
Study 16413652 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous augmented feedback
Number of subjects: 36
Study 16413652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent (66% of the time) augmented feedback
Number of subjects: 36
Study 16413652 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 36
Study 14499422 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (10 mg to 40 mg q12h)
Number of subjects: 36
Study 11273538 — intervention group
Group type: EXPERIMENTAL
Intervention: antacid-acid
Number of subjects: 12
Study 11273538 — intervention group
Group type: EXPERIMENTAL
Intervention: acid-antacid
Number of subjects: 12
Study 11273538 — intervention group
Group type: EXPERIMENTAL
Intervention: acid-acid
Number of subjects: 12
Study 11273538 — intervention group
Group type: COMPARATOR
Intervention: antacid-antacid (control)
Number of subjects: 12
Study 9089851 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of nalbuphine intravenously
Number of subjects: 31
Study 9089851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9089851 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0, 0.3, 0.6, 0.9, 1.2, and 1.5 mg/kg of 2‐chloroprocaine
Number of subjects: 31
Study 7693504 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine, 180 mg, by mouth
Number of subjects: 10
Study 7693504 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide, 0.5 mg, nebulized
Number of subjects: 10
Study 7693504 — intervention group
Group type: EXPERIMENTAL
Intervention: both active drugs together (terfenadine and ipratropium bromide)
Number of subjects: 10
Study 7693504 — intervention group
Group type: COMPARATOR
Intervention: placebo preparations (by mouth and by nebulizer)
Number of subjects: 10
Study 3536171 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose sublingual therapy with house dust mite
Number of subjects: 18
Study 29420194 — intervention group
Group type: EXPERIMENTAL
Intervention: RT with lid manipulation (LM)
Number of subjects: 103
Study 29420194 — intervention group
Group type: COMPARATOR
Intervention: RT without lid manipulation (LM)
Number of subjects: 103
Study 29420194 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 103
Study 26856586 — intervention group
Group type: EXPERIMENTAL
Intervention: SpineJack® (SJ)
Number of subjects: 30
Study 26856586 — intervention group
Group type: COMPARATOR
Intervention: Balloon Kyphoplasty (BKP)
Number of subjects: 30
Study 24958751 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 2137
Study 21512799 — intervention group
Group type: EXPERIMENTAL
Intervention: General fitness training performed as leg‐bicycling (GFT)
Number of subjects: 39
Study 21512799 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific strength training of the neck/shoulder muscles (SST)
Number of subjects: 39
Study 21512799 — intervention group
Group type: COMPARATOR
Intervention: Reference intervention without physical exercise
Number of subjects: 39
Study 20368520 — intervention group
Group type: COMPARATOR
Intervention: UFH 70 U/kg
Number of subjects: 503
Study 20368520 — intervention group
Group type: EXPERIMENTAL
Intervention: M118 50 IU/kg IV
Number of subjects: 503
Study 20368520 — intervention group
Group type: EXPERIMENTAL
Intervention: M118 75 IU/kg IV
Number of subjects: 503
Study 20368520 — intervention group
Group type: EXPERIMENTAL
Intervention: M118 100 IU/kg IV
Number of subjects: 503
Study 19010733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs' micrographic surgery (MMS) for primary BCC
Number of subjects: 612
Study 19010733 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision for primary BCC
Number of subjects: 612
Study 19010733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs' micrographic surgery (MMS) for recurrent BCC
Number of subjects: 612
Study 19010733 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision for recurrent BCC
Number of subjects: 612
Study 19010733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of MMS for primary BCC
Number of subjects: 612
Study 19010733 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness of surgical excision for primary BCC
Number of subjects: 612
Study 19010733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of MMS for recurrent BCC
Number of subjects: 612
Study 19010733 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness of surgical excision for recurrent BCC
Number of subjects: 612
Study 19010733 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness ratio for primary BCC
Number of subjects: 612
Study 19010733 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness ratio for recurrent BCC
Number of subjects: 612
Study 15755834 — intervention group
Group type: COMPARATOR
Intervention: Wheat products fortified with 0 mg Zn (group Zn-0)
Number of subjects: 41
Study 15755834 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat products fortified with 3 mg Zn (group Zn-3)
Number of subjects: 41
Study 15755834 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat products fortified with 9 mg Zn (group Zn-9)
Number of subjects: 41
Study 12585143 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuzi Yanzong Pill (WZYZP)
Number of subjects: 38
Study 12585143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 10029942 — intervention group
Group type: EXPERIMENTAL
Intervention: Gillet test
Number of subjects: 41
Study 8748919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant for embryo transfer (ET)
Number of subjects: 211
Study 8748919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 211
Study 8748919 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization after ET
Number of subjects: 211
Study 2328178 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.1, 0.2, 0.4 or 1 mg kg‐1
Number of subjects: 100
Study 2328178 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium with enflurane 2% discontinued
Number of subjects: 100
Study 6788282 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium sucrose biscuits
Number of subjects: 6
Study 6788282 — intervention group
Group type: COMPARATOR
Intervention: Placebo biscuits
Number of subjects: 6
Study 6788282 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 6
Study 31676389 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 g/day)
Number of subjects: 11
Study 31676389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30188800 — intervention group
Group type: EXPERIMENTAL
Intervention: SRA (simple resistance activities)
Number of subjects: 19
Study 30188800 — intervention group
Group type: COMPARATOR
Intervention: SIT (five hours uninterrupted sitting)
Number of subjects: 19
Study 30188800 — intervention group
Group type: EXPERIMENTAL
Intervention: SRA
Number of subjects: 19
Study 26720202 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol 2 (test bolus method)
Number of subjects: 110
Study 26720202 — intervention group
Group type: COMPARATOR
Intervention: Protocol 1 (fixed delay time scan method)
Number of subjects: 110
Study 24468043 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 50
Study 24468043 — intervention group
Group type: COMPARATOR
Intervention: Balloon-occluded retrograde transvenous obliteration (BRTO)
Number of subjects: 50
Study 22768888 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose pentagon model (GPM)
Number of subjects: 108
Study 19969485 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous coronoid process pedicled on temporal muscle grafts (ACPTMG)
Number of subjects: 48
Study 19969485 — intervention group
Group type: COMPARATOR
Intervention: Autogenous free coronoid process grafts (AFCPG)
Number of subjects: 48
Study 17005577 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot biopsy forceps (with electrocoagulation)
Number of subjects: 39
Study 17005577 — intervention group
Group type: COMPARATOR
Intervention: Cold biopsy forceps (without electrocoagulation)
Number of subjects: 39
Study 17005577 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot biopsy forceps
Number of subjects: 39
Study 17005577 — intervention group
Group type: COMPARATOR
Intervention: Cold biopsy forceps
Number of subjects: 39
Study 15803263 — intervention group
Group type: EXPERIMENTAL
Intervention: Job performance with heavy physical exertion
Number of subjects: 108
Study 15803263 — intervention group
Group type: COMPARATOR
Intervention: Expected risk without heavy physical exertion
Number of subjects: 108
Study 15803263 — intervention group
Group type: COMPARATOR
Intervention: Expected cardiac events related to job performance
Number of subjects: 108
Study 15803263 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk for observed cardiac events
Number of subjects: 108
Study 15803263 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative risk for expected events compared to basal risk
Number of subjects: 108
Study 11877616 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic measurement of inferior humeral displacement at 15 degrees of forward flexion and 70 degrees of abduction and neutral rotation.
Number of subjects: 143
Study 9643568 — intervention group
Group type: EXPERIMENTAL
Intervention: LRP overexpression (LRP+) defined by expression of LRP 56 in at least 20% of marrow blasts.
Number of subjects: 41
Study 9643568 — intervention group
Group type: EXPERIMENTAL
Intervention: LRP overexpression (LRP+)
Number of subjects: 41
Study 9643568 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline‐AraC intensive chemotherapy
Number of subjects: 41
Study 9643568 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose AraC
Number of subjects: 41
Study 9138874 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (laparoscopy)
Number of subjects: 192
Study 9138874 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy (control)
Number of subjects: 192
Study 9138874 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 192
Study 3063328 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-antibody depleted grafts (T10B9 and T12A10)
Number of subjects: 34
Study 3063328 — intervention group
Group type: COMPARATOR
Intervention: One-antibody depleted grafts (T10B9)
Number of subjects: 34
Study 30307720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini dental implants
Number of subjects: 0
Study 30307720 — intervention group
Group type: COMPARATOR
Intervention: Conventional dental implants
Number of subjects: 0
Study 27649676 — intervention group
Group type: EXPERIMENTAL
Intervention: BIFICO treatment (oral admission)
Number of subjects: 215
Study 27649676 — intervention group
Group type: COMPARATOR
Intervention: Control group (primary disease treatment alone)
Number of subjects: 215
Study 24885377 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous catheter ablation (n = 100)
Number of subjects: 150
Study 24885377 — intervention group
Group type: COMPARATOR
Intervention: Surgical ablation (n = 50)
Number of subjects: 150
Study 22335234 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation with different pulse types at 38.2°C and 40.7°C heat intensity
Number of subjects: 14
Study 22335234 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic continuous stimulation at 7 Hz
Number of subjects: 14
Study 22335234 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing heat during electrical stimulation
Number of subjects: 14
Study 22335234 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stimulation intensity
Number of subjects: 14
Study 20359612 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice plus exhaled CO analysis
Number of subjects: 578
Study 20359612 — intervention group
Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 578
Study 18322901 — intervention group
Group type: EXPERIMENTAL
Intervention: ARMOR training
Number of subjects: 8
Study 18322901 — intervention group
Group type: COMPARATOR
Intervention: EMG‐triggered neuromuscular electrical stimulation (EMG‐NMES)
Number of subjects: 8
Study 18322901 — intervention group
Group type: COMPARATOR
Intervention: EMG‐NMES
Number of subjects: 8
Study 15983319 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (simvastatin 20 mg daily after cerivastatin 0.4 mg daily)
Number of subjects: 250
Study 15983319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 15983319 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 250
Study 15138154 — intervention group
Group type: COMPARATOR
Intervention: GHRH alone
Number of subjects: 8
Study 15138154 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GHRH and arginine
Number of subjects: 8
Study 10699602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 240 mg polyestradiol phosphate (PEP) every second week for the first 8 weeks followed by a maintenance dose of 240 mg every month (n = 458)
Number of subjects: 915
Study 10699602 — intervention group
Group type: COMPARATOR
Intervention: Total androgen ablation (TAA) via bilateral orchiectomy or triptorelin 3.75 mg every month combined with flutamide 250 mg three times daily (n = 457)
Number of subjects: 915
Study 9382545 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hepatic arterial infusion of 5‐FU (360 mg/m2/day x 5 days/week x 4 weeks)
Number of subjects: 14
Study 9382545 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous infusion of 5‐FU (360 mg/m2/day x 2 weeks)
Number of subjects: 14
Study 8334911 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundus‐III (a composite herbal recipe for Huoxue‐Huayu)
Number of subjects: 80
Study 8334911 — intervention group
Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 80
Study 3962571 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-barrelled 16F-Argyle Salem sump tube, length 120 cm, size 16 CH
Number of subjects: 80
Study 3962571 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-barrelled stomach tube, length 80 cm, size 25 CH
Number of subjects: 80
Study 2662100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy
Number of subjects: 198
Study 2662100 — intervention group
Group type: COMPARATOR
Intervention: Scleral buckling
Number of subjects: 198
Study 31992367 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at EX-HN3, LI20, and EX-HN8 thrice per week for a total of 12 sessions plus acupoint application at DU14, BL13, EX-BI, and RN22
Number of subjects: 120
Study 31992367 — intervention group
Group type: COMPARATOR
Intervention: Sham AAP
Number of subjects: 120
Study 31492651 — intervention group
Group type: EXPERIMENTAL
Intervention: ozanimod 1.0 mg
Number of subjects: 1346
Study 31492651 — intervention group
Group type: EXPERIMENTAL
Intervention: ozanimod 0.5 mg
Number of subjects: 1346